EZH2
About
Location: 7q36.1
Mappings
Biomarkers
EZH2 is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| EZH2 p.Y646N | Somatic Variant | 1 | 1 |
| EZH2 p.Y646F | Somatic Variant | 1 | 1 |
| EZH2 p.Y646H | Somatic Variant | 1 | 1 |
| EZH2 p.Y646S | Somatic Variant | 1 | 1 |
| EZH2 p.Y646C | Somatic Variant | 1 | 1 |
| EZH2 p.A862G | Somatic Variant | 1 | 1 |
| EZH2 p.A692V | Somatic Variant | 1 | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | EZH2 p.Y646N | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646F | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646H | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646S | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.Y646C | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.A862G | Follicular Lymphoma | Tazemetostat | |
| FDA (1) | EZH2 p.A692V | Follicular Lymphoma | Tazemetostat |